View Pages
Stock Movers: Novartis Drops After Trial Failure; Boston Scientific Cyberattack; Intel Rises
Bloomberg Stock Movers: Novartis tumbles after late-stage trial failure; Boston Scientific hit by cyberattack disrupting shipments and guidance; Intel rises on reports of upcoming chip price hikes.
Editorial companion
What stands out
Bloomberg’s Stock Movers highlighted two very different corporate shocks: Boston Scientific warning that a cybersecurity incident is hampering shipments and will dent sales and earnings, while Intel got a lift from reports it may raise chip prices next month. One is an operational stoppage that removes revenue at the source, the other is a pricing lever that can restore margin without selling more units. With central bank and inflation headlines back in play, both stories matter for cash flow and how investors price cyclical tech and health care names.
View Pages
Bullish Gator Snapshot
Current ratings and signals
Boston Scientific (BSX)
Neutral
BSX rates Neutral overall. The fundamental read is neutral: the company passes 6 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 3.07); revenue is growing about 16.6% per year; net income is growing about 66.9% per year. The technical picture is bearish: price is 20.8% below the 200-day moving average; 0.4% above the 50-day; the 50/200 relationship is in a Death cross. Sentiment is bearish (composite 45/100), based on 5 news articles from recent coverage.
Intel (INTC)
Neutral
INTC rates Neutral overall. The fundamental read is neutral: the company passes 6 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 3.82); revenue is declining about 5.5% per year; net income is declining about 78.9% per year. The technical picture is bearish: price is 5.1% above the 200-day moving average; 11.2% below the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 80/100), based on 6 news articles and 2 qualified videos from recent coverage.